title: The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
authors.forename: James B
authors.initials: JB
authors.lastname: Galloway
authors.forename: Kimme L
authors.initials: KL
authors.lastname: Hyrich
authors.forename: Louise K
authors.initials: LK
authors.lastname: Mercer
authors.forename: William G
authors.initials: WG
authors.lastname: Dixon
authors.forename: Kath D
authors.initials: KD
authors.lastname: Watson
authors.forename: Mark
authors.initials: M
authors.lastname: Lunt
authors.forename: Deborah P M
authors.initials: DP
authors.lastname: Symmons
mesh_terms: D017677:Age Distribution; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001424:Bacterial Infections / Q000453:epidemiology* / Q000209:etiology* / Q000503:physiopathology; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D053590:Interleukin 1 Receptor Antagonist Protein / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012042:Registries; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D012955:Societies, Medical; D015996:Survival Rate; D006113:United Kingdom
chemical_list: D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein